Pharmacogenomics News and Research

RSS

The terms pharmacogenomics and pharmacogenetics are often used interchangeably to describe a field of research focused on how genes affect individual responses to medicines. Whether a medicine works well for you—or whether it causes serious side effects—depends, to a certain extent, on your genes.

Can IT fuel the race to the $1,000 human genome?

Ever wonder if you have a genetic disposition to a certain disease, or why a medicine works for your friend, but not for you?

21 Apr 2008

GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure

About 40 percent of African-Americans have a genetic variant that can protect them after heart failure and prolong their lives, according to research conducted at Washington University School of Medicine in St. Louis and collaborating institutions.

20 Apr 2008

A genetic variation mimics effect of heart failure medications - may explain why beta-blockers do not work for all patients

A genetic variation, found predominantly in African Americans, protects some people with heart failure, enabling them to live longer than expected. That's the conclusion of a research team led by investigators at the University of Maryland School of Medicine in Baltimore and the Washington University School of Medicine in St. Louis.

20 Apr 2008

Global Alliance for Pharmacogenomics

Leaders at the National Institutes of Health and the Center for Genomic Medicine in Japan have signed a letter of intent creating a Global Alliance for Pharmacogenomics.

15 Apr 2008

Body mass index higher among bariatric surgery patients with 2 genetic variations

The combination of two obesity-related genetic variations may be associated with an increased body mass index (BMI) among severely obese patients undergoing bariatric weight loss surgery, according to a report in the March issue of Archives of Surgery.

18 Mar 2008

Genetic variant predicts antipsychotic response for schizophrenia patients by ethnicity

Schizophrenia is a developmental disorder with a large genetic component contributing to increased risk.

9 Jan 2008

FDA Critical Path Initiative addresses differences between women's and men's health outcomes

Advanced medical technology and analysis methods now being promoted through the Food and Drug Administration's Critical Path Initiative to facilitate the development of drugs, biologics and devices can help address differences between women and men in the detection and treatment of disease, according to a paper published in the Winter 2007 issue of Drug Discovery Today: Technologies.

20 Dec 2007

Genetic markers for mental illness

Researchers have discovered natural genetic differences that might help predict the most effective antipsychotic drugs for particular patients with mental disorders such as schizophrenia, Parkinson's and drug addiction.

4 Dec 2007

Some with breast cancer stop taking aromatase inhibitors because of joint and muscle pain

More than 10 percent of women with breast cancer stopped taking a commonly prescribed drug because of joint and muscle pain, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

10 Sep 2007

FDA should amend the product information for irinotecan

Not everyone needs a genetic test before taking the cancer drug irinotecan, and the U.S. Food and Drug Administration should modify its prescription guidelines to say so, according to researchers at the University of North Carolina at Chapel Hill.

29 Aug 2007

FDA approves updated labeling for Warfarin (Coumadin)

The U.S. Food and Drug Administration has announced the approval of updated labeling for the widely used blood-thinning drug, Coumadin, to explain that people's genetic makeup may influence how they respond to the drug.

17 Aug 2007

New study emphasizes the importance of metabolomics to the advent of personalized medicine

International experts have collaborated on a comprehensive collection of reviews focusing on the emerging interface between metabolomics and pharmacogenomics.

24 Oct 2006

FDA advisory panel recommends adding warning label to Tamoxifen

An FDA advisory panel on Wednesday recommended that a warning label be added to tamoxifen, an agency-approved drug for treating and preventing breast cancer, the AP/Seattle Post-Intelligencer reports (Bridges, AP/Seattle Post-Intelligencer, 10/18).

19 Oct 2006

An outsider's view of chronic fatigue syndrome may provide clues to how we perceive

Clinical methodology and its implications for the study of therapeutic interventions for chronic fatigue syndrome (CFS).

28 Jun 2006

Prozac saves thousands of lives

A new study should help alleviate any concern over a link between the use of certain antidepressants and suicide.

13 Jun 2006

Genetic and environmental factors impact chronic fatigue syndrome patients

People who suffer from chronic fatigue syndrome (CFS) have a genetic make up that affects the body's ability to adapt to change, according to a series of papers released last week by the Centers for Disease Control and Prevention (CDC).

2 May 2006

Genetic clue found to Chronic Fatigue Syndrome

According to researchers from the Centers for Disease Control and Prevention (CDC), in the United States, there may well be a genetic reason why some people develop Chronic Fatigue Syndrome (CFS).

24 Apr 2006

St. Jude projects 90 percent cure rate for acute lymphoblastic leukemia

The cure rate for the once almost universally fatal childhood cancer acute lymphoblastic leukemia (ALL) could reach 90 percent in the near future, thanks to improvements in diagnosis and treatment over the past four decades, according to investigators at St. Jude Children's Research Hospital.

11 Jan 2006

Pharmacogenetics can reduce health care costs

Chances are good that a medication you take is one of several drugs that can be affected by genetic factors, according to researchers at Washington University School of Medicine in St. Louis and the St. Louis College of Pharmacy.

5 Jan 2006

High blood pressure research advances efforts to tailor drugs to individual patients

Having high blood pressure and a particular genetic alteration dramatically increases the risk of heart attack, stroke or death, and may explain why some hypertensive patients fare worse than others - even if they take the same medication, University of Florida researchers announced.

26 Nov 2005